We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
Cap. Flow
+$393M
Cap. Flow %
4.22%
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$348M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$229M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$100M
4
CCCC icon
C4 Therapeutics
CCCC
+$91.6M
5
KRON
Kronos Bio
KRON
+$87.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$190M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$112M
3
IMMU
Immunomedics Inc
IMMU
+$77.6M
4
BPMC
Blueprint Medicines
BPMC
+$61.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.2%
2 Financials 0.33%
3 Industrials 0.29%
4 Materials 0.22%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
101
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$11.1M 0.12%
+1,000,000
New +$10.7M
SCPE.U
102
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
$11M 0.12%
1,000,000
– –
CRIS icon
103
Curis
CRIS
$9.71M
$10.2M 0.11%
+3,125
New +$3.75M
MRVI icon
104
Maravai LifeSciences
MRVI
$972M
$9.82M 0.11%
+350,000
New +$9.75M
VRAY
105
DELISTED
ViewRay, Inc.
VRAY
$9.37M 0.1%
2,451,748
– –
RVMD icon
106
Revolution Medicines
RVMD
$38.5B
$8.88M 0.1%
224,224
– –
PSTX
107
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$8.64M 0.09%
787,745
– –
DYN icon
108
Dyne Therapeutics
DYN
$4.15B
$8.4M 0.09%
400,000
– –
SHC icon
109
Sotera Health
SHC
$5B
$8.23M 0.09%
+300,000
New +$8.05M
AQST icon
110
Aquestive Therapeutics
AQST
$452M
$7.41M 0.08%
1,385,720
-364,280
-21% -$2.18M
SNDX icon
111
Syndax Pharmaceuticals
SNDX
$1.7B
$6.67M 0.07%
+300,000
New +$6.22M
VINC
112
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$6.27M 0.07%
+15,000
New +$4.73M
SGTX
113
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$6M 0.06%
+9,615
New +$4.36M
OBIO icon
114
Orchestra BioMed
OBIO
$228M
$5.76M 0.06%
450,000
– –
TNGX icon
115
Tango Therapeutics
TNGX
$4.21B
$5.72M 0.06%
500,000
– –
PHR icon
116
Phreesia
PHR
$689M
$5.43M 0.06%
+100,000
New +$4.29M
CHFW.U
117
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$5.24M 0.06%
+500,000
New +$5.11M
DFHTU
118
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$4.5M 0.05%
300,000
– –
MASS icon
119
908 Devices
MASS
$312M
$4.41M 0.05%
+77,500
New +$4.53M
AVXL icon
120
Anavex Life Sciences
AVXL
$231M
$4.21M 0.05%
+780,007
New +$4.11M
PTGX icon
121
Protagonist Therapeutics
PTGX
$8.55B
$4.1M 0.04%
+203,591
New +$4.38M
MOTS
122
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$3.91M 0.04%
14,035
– –
MTEM
123
DELISTED
Molecular Templates, Inc.
MTEM
$3.87M 0.04%
27,455
-137,487
-83% -$20.3M
BNR
124
Burning Rock Biotech
BNR
$93M
$3.46M 0.04%
15,000
– –
GRTX
125
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.33M 0.04%
325,000
– –
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.

  • Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
  • Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
  • Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
  • Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.